In the past week, EVH stock has gone down by -1.28%, with a monthly decline of -9.69% and a quarterly plunge of -5.67%. The volatility ratio for the week is 3.27%, and the volatility levels for the last 30 days are 3.04% for Evolent Health Inc. The simple moving average for the past 20 days is -4.41% for EVH’s stock, with a -0.43% simple moving average for the past 200 days.
Is It Worth Investing in Evolent Health Inc (NYSE: EVH) Right Now?
The 36-month beta value for EVH is also noteworthy at 1.55. There are mixed opinions on the stock, with 6 analysts rating it as a “buy,” 7 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The public float for EVH is 109.55M, and at present, short sellers hold a 9.68% of that float. The average trading volume of EVH on April 25, 2024 was 937.60K shares.
EVH) stock’s latest price update
Evolent Health Inc (NYSE: EVH)’s stock price has gone decline by -2.89 in comparison to its previous close of 30.13, however, the company has experienced a -1.28% decrease in its stock price over the last five trading days. Zacks Investment Research reported 2024-03-14 that The average of price targets set by Wall Street analysts indicates a potential upside of 34.5% in Evolent Health (EVH). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Analysts’ Opinion of EVH
Many brokerage firms have already submitted their reports for EVH stocks, with Citigroup repeating the rating for EVH by listing it as a “Buy.” The predicted price for EVH in the upcoming period, according to Citigroup is $40 based on the research report published on April 22, 2024 of the current year 2024.
Oppenheimer, on the other hand, stated in their research note that they expect to see EVH reach a price target of $45. The rating they have provided for EVH stocks is “Outperform” according to the report published on March 01st, 2024.
Barclays gave a rating of “Overweight” to EVH, setting the target price at $39 in the report published on January 03rd of the current year.
EVH Trading at -8.24% from the 50-Day Moving Average
After a stumble in the market that brought EVH to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -20.27% of loss for the given period.
Volatility was left at 3.04%, however, over the last 30 days, the volatility rate increased by 3.27%, as shares sank -8.93% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -6.99% lower at present.
During the last 5 trading sessions, EVH fell by -1.28%, which changed the moving average for the period of 200-days by -2.95% in comparison to the 20-day moving average, which settled at $30.47. In addition, Evolent Health Inc saw -11.41% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at EVH starting from Blackley Seth, who sale 141,000 shares at the price of $26.54 back on Dec 05 ’23. After this action, Blackley Seth now owns 637,645 shares of Evolent Health Inc, valued at $3,741,475 using the latest closing price.
McCarthy Daniel Joseph, the PRESIDENT of Evolent Health Inc, sale 11,000 shares at $30.00 during a trade that took place back on Nov 15 ’23, which means that McCarthy Daniel Joseph is holding 198,333 shares at $330,000 based on the most recent closing price.
Stock Fundamentals for EVH
Current profitability levels for the company are sitting at:
- -0.03 for the present operating margin
- 0.23 for the gross margin
The net margin for Evolent Health Inc stands at -0.06. The total capital return value is set at -0.03. Equity return is now at value -11.73, with -5.03 for asset returns.
Based on Evolent Health Inc (EVH), the company’s capital structure generated 0.38 points at debt to capital in total, while cash flow to debt ratio is standing at 0.22. The debt to equity ratio resting at 0.6. The interest coverage ratio of the stock is -1.16.
Currently, EBITDA for the company is 46.38 million with net debt to EBITDA at 9.74. When we switch over and look at the enterprise to sales, we see a ratio of 1.95. The receivables turnover for the company is 4.4for trailing twelve months and the total asset turnover is 0.73. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.01.
Conclusion
In summary, Evolent Health Inc (EVH) has had a bad performance as of late. Analysts have bullish opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
